Which statement best describes a short-acting beta-agonist (SABA) in asthma management?

Which statement best describes a short-acting beta-agonist (SABA) in asthma management?

• A. Controller therapy used daily
• B. Reduces airway inflammation
• C. Not used in COPD
• D. Quick relief bronchodilator; rescue only

Answer: (D)

Short-acting beta-agonists provide rapid bronchodilation by stimulating beta-2 receptors on airway smooth muscle, which relaxes the muscles and opens the airways within minutes. Because their effect is brief, they’re used for immediate relief of acute symptoms or just before exercise to prevent symptoms, rather than as ongoing daily control therapy. They do not reduce airway inflammation—that requires anti-inflammatory medications like inhaled corticosteroids. In COPD, these agents are also used as quick-relief bronchodilators, further illustrating they’re for rescue rather than long-term control. So the best description is that they are quick relief bronchodilators for rescue use.